| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
| Targets |
24R-Calcipotriol targets the vitamin D receptor (VDR), a nuclear receptor involved in the regulation of cell proliferation, differentiation, and immune function. As a VDR ligand, it modulates gene transcription and exhibits antiproliferative activity against various cancer cell lines.
|
|---|---|
| ln Vitro |
In vitro, 24R-Calcipotriol exhibits antiproliferative activity against human cancer cell lines including HL-60, HL60/MX2, MCF-7, T47D, SCC-25, and mouse WEHI-3 cells. It induces differentiation and modulates cell growth in various in vitro models. Studies have shown that combined treatment with Vitamin D analogues is more effective than cytostatics alone.
|
| ln Vivo |
In vivo, 24R-Calcipotriol has been investigated for its antitumor effects in mouse models. Studies have demonstrated that combination treatment with Vitamin D analogues and cytostatics enhances antitumor efficacy compared to cytostatics alone. The compound also modulates immune responses and exhibits anti-inflammatory effects.
|
| Enzyme Assay |
In vitro receptor binding assays for 24R-Calcipotriol are performed using VDR-containing nuclear extracts or recombinant VDR protein. Radiolabeled calcitriol or other VDR ligands are used as tracers, and binding affinity is determined by measuring displacement via scintillation counting. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for 24R-Calcipotriol are conducted using cancer cell lines such as HL-60, MCF-7, or SCC-25. Cells are treated with serial dilutions of the compound (0.1 nM to 10 uM) for 24-72 hours. Cell proliferation is assessed by MTT or CCK-8 assays. Differentiation markers are evaluated by flow cytometry or qPCR. Apoptosis is measured by Annexin V/PI staining.
|
| Animal Protocol |
In vivo studies for 24R-Calcipotriol are conducted in mouse xenograft models bearing human tumor cells. The compound is administered via intraperitoneal or oral routes at doses typically ranging from 0.1-10 ug/kg. Tumor volume is measured, and tumor growth inhibition (TGI) is calculated. Combination studies with cytostatics are performed to evaluate synergistic effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 24R-Calcipotriol are similar to those of other Vitamin D analogues. The compound has a molecular weight of 412.6 and formula C27H40O3. It is unstable in solution and should be stored at -20degC, protected from light, and under nitrogen. Oral bioavailability and half-life data are not extensively characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for 24R-Calcipotriol are limited. As a Vitamin D analogue, standard safety concerns include potential effects on calcium homeostasis and hypercalcemia at high doses. No significant toxicity has been reported at therapeutic doses. The compound is for research use only.
|
| References |
|
| Additional Infomation |
24R-Calcipotriol (PRI 2202, Tacalcitol) is a synthetic Vitamin D3 analogue and an impurity of Calcipotriol. It has been investigated for its potential antitumor effects and combination therapy with cytostatics. Tacalcitol is approved in some regions for the treatment of psoriasis. The compound is for research use only and not for human therapeutic application in this context.
|
| Molecular Formula |
C₂₇H₄₀O₃
|
|---|---|
| Molecular Weight |
412.60
|
| Exact Mass |
412.298
|
| CAS # |
112827-99-3
|
| PubChem CID |
9547353
|
| Appearance |
White solid powder
|
| LogP |
5.09
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
743
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](/C=C/[C@@H](C1CC1)O)[C@H]2CC[C@@H]\3[C@@]2(CCC/C3=C\C=C/4\C[C@H](C[C@@H](C4=C)O)O)C
|
| InChi Key |
LWQQLNNNIPYSNX-CIJZWTHJSA-N
|
| InChi Code |
InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25+,26+,27-/m1/s1
|
| Chemical Name |
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
|
| Synonyms |
PRI-2202 PRI2202 PRI 2202 Impurity D of Calcipotriol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (3). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4237 mL | 12.1183 mL | 24.2365 mL | |
| 5 mM | 0.4847 mL | 2.4237 mL | 4.8473 mL | |
| 10 mM | 0.2424 mL | 1.2118 mL | 2.4237 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
